BK-5F-NM-AMT

Clinical data
Other names	βk-5F-NM-αMT; β-Keto-5-fluoro-N-methyl-αMT; β-Keto-5-fluoro-N-methyl-AMT; α,N-Dimethyl-5-fluoro-β-ketotryptamine; β-Oxo-5-fluoro-α-methyl-NMT
Drug class	Monoamine releasing agent
Identifiers
IUPAC name 1-(5-fluoro-1H-indol-3-yl)-2-(methylamino)propan-1-one
PubChem CID	162765676
Chemical and physical data
Formula	C12H13FN2O
Molar mass	220.247 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C(=O)C1=CNC2=C1C=C(C=C2)F)NC
InChI InChI=1S/C12H13FN2O/c1-7(14-2)12(16)10-6-15-11-4-3-8(13)5-9(10)11/h3-7,14-15H,1-2H3 Key:NONYEOWAEONGSG-UHFFFAOYSA-N

BK-5F-NM-AMT, or βk-5F-NM-αMT, also known as β-keto-5-fluoro-N-methyl-αMT or α,N-dimethyl-5-fluoro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.^[1]

It is known to induce the release of serotonin and dopamine, with respective EC₅₀Tooltip half-maximal effective concentration values of 190 nM and 620 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.^[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT₁, 5-HT₂, and 5-HT₃ receptors.^[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).^[1]

BK-5F-NM-AMT was first described in the literature by 2023.^[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.^[1] BK-5F-NM-AMT is the 5-fluoro derivative of BK-NM-AMT.^[1][3][4] Other analogues of the drug include BK-5Cl-NM-AMT and BK-5Br-NM-AMT.^[1]

• Substituted α-alkyltryptamine
• Substituted β-ketotryptamine
• 5-Fluoro-AMT

• β-Oxo-5-fluoro-α-methyl-NMT (BK-5F-NM-AMT) - Isomer Design